Orlando—A small study of 2 cholesterol-modifying drugs presented at the American Heart Association's annual Scientific Sessions held here in November prompted comments and questions involving much larger issues, ranging from physician prescribing patterns to the role of clinical effectiveness in drug approvals.
The study compared 2 treatment strategies, using statin therapy and adding either ezetimibe or extended-release niacin, to diminish cardiovascular disease risk by modifying cholesterol levels in men and women with coronary heart disease or a coronary heart disease risk equivalent: diabetes mellitus, a 10-year Framingham risk score (used to estimate risk of coronary heart disease) of 20% or more, or a coronary calcium score above 200 for women or 400 for men.
Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more
Subscribe for full-text access to content from 1998 forward and a host of useful features
Activate your current subscription (AMA members and current subscribers)
Purchase Online Access to this article for 24 hours
Graphic Jump Location
Using ultrasonography, researchers measure carotid intima-media thickness, a surrogate marker for atherosclerosis progression.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 3
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
and access these and other features:
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.